Skip to main content
Premium Trial:

Request an Annual Quote

OriGene Raises $21.3M in Series C Funding

NEW YORK (GenomeWeb News) – OriGene Technologies today announced the completion of its $21.3 million Series C financing round.

Qiming Venture Partners and Kleiner Perkins Caufield Byers China led the round, while existing investor IDG-Accel also participated, OriGene said.

The company intends to use the financing to "advance our growth strategy and operations," Wei-Wu He, OriGene's chairman and CEO, said in a statement, without elaborating.

Based in Rockville, Md., the company develops genomic research and diagnostic products. Its flagship product is the cDNA clone collection, a searchable gene bank with more than 30,000 human full-length TrueClone cDNA collections and more than 25,000 TrueORF cDNA clones, it said on its website.

Additionally, the company has developed "ultra-sensitive" monoclonal antibodies called UltraMAB.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.